

He holds degrees in Chemistry (Univ. Ramon Llull,1994) and Chemical Engineering (IQS, 1995). After obtaining a Ph D in Organic Chemistry (University of Barcelona, 1999) he joined the group of Lewis Kay in Toronto for a post-doctoral stay (University of Toronto, 2000-2004). He was then recipient of a Ramon y Cajal reincorporation contract at the Parc Cientific de Barcelona (2004-2006) and he currently is group leader at the CIC bioGUNE. His research line focuses of the use of nuclear magnetic resonance (NMR) to the study of biologically relevant proteins and enzymes, paying special attention to the delicate balance existing between protein stability and dynamics. Such knowledge is applied for the development of new compounds with therapeutic activity, specifically in the field of rare diseases. He have published more than 55 papers with a total number of citations (1998-2015) of 2050 and an h-index of 17. He was the Spanish delegate for the trans domain of the COST program (2009-2014). He was awarded the prize of the Real Sociedad Española de Química (2004) and the Spanish NMR group prize (2005). He currently is the president of the Spanish NMR group.
Latest Publications
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2007
Protein stability (thermodynamic and kinetic) drives the biophysical properties of the polypeptide chain (protein folding) and the protein's concentration in the cellular environment (protein homeostasis). It is the result of a delicate balance between inter- and intramolecular interactions, which can be easily altered by mutations and/or upon changes in the composition of the surrounding media. In this context, NMR spectroscopy offers a plethora of suitable experiments to investigate protein stability. In our laboratory we are currently interested in the following topics:
-
Pharmacological chaperones. Rare diseases (~7000 identified to date) are an area of significant medical need affecting an estimated 350 million people worldwide, with ~95% having no currently approved drug treatment. They are often produced by inherited mutations affecting the activity of a protein and It is becoming increasily clear that, most frequently, a mutation destabilizes the protein/enzyme, ultimately affecting its intracellular homeostasis. In this context, pharmacological chaperones (small molecules which bind to the protein, restoring stability and activity without affecting its function) can be applied to many diseases. In our laboratory we are investigating new methods (NMR, biophysical and biochemical) for the discovery and characterization of pharmacological chaperones against a set of diseases: congenital eryhtropoietic porphyria, tyrosianemia.
- Environmental modulation of enzyme stability. The high catalytic efficiency and the exquisite enantioselectivity of an enzyme has been employed in some industrial processes to upgrade their properties in order to make them more environmentally-friendly. However, large scale industrial implementation of biotechnological reactions is often limited by the marginal stability of the enzyme in the reactor conditions. In our laboratory we employ NMR and circular dichroism to investigate the effect of external crowding agents to improve the activity and stability of several enzymes. Specifically, we are investigating the mechanism for protein haloadaptation by a combined use of site directed mutagenesis and high-resolution NMR spectroscopy.
-
General Director
José M Mato
IMI2 Programme IKERBASQUE RESEARCH FELLOW -
Gabriel Ortega Quintanilla
Ikerbasque Research Fellow RESEARCH ASSISTANT -
Nieves Embade
-
Fernando Lopitz Otsoa
SPECIALIST -
Rubén Gil Redondo
-
Beatriz González Valle
POSTDOCTORAL RESEARCHER -
David Fernández Ramos
-
Ganeko Bernardo
-
Andreas Schedlbauer
-
Alain Ibañez de Opakua Lopez de Abetxuko
TECHNICIANS / DOCTORAL CANDIDATES -
Maria de los Reyes Luque Urbano
-
Cristina Garrido
-
Karen Salua Alarcón Morales
-
Jon Bilbao García
-
Ricardo Diogo Alves Conde
-
Sara Martín Ramos
-
Jon Gil Martinez
-
Riccardo Scarin
-
Alba Pejenaute Pejenaute
-
Uxue Hermoso Martínez
-
Tania Pereira Ortuzar
-
Margarita Gómez Galán
-
Ana Laín
-
Ángela de Diego Rodríguez
-
Virginia Gutiérrez de Juan
-
Maider Bizkarguenaga Uribiarte
-
Pablo Herrero Alfonso
Members
Latest Publications
Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19
Bruzzone, C;Conde, R;Embade, N;Mato, JM;Millet, O
FRONTIERS IN MOLECULAR BIOSCIENCES
2023-02-15
Impaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in Hepatocytes
Cano, A;Vazquez-Chantada, M;Conde-Vancells, J;Gonzalez-Lahera, A;Mosen-Ansorena, D;Blanco, FJ;Clement, K;Aron-Wisnewsky, J;Tran, A;Gual, P;Garcia-Monzon, C;Caballeria, J;Castro, A;Martinez-Chantar, ...
BIOMEDICINES
2023-02-01
Protoporphyrin IX Binds to Iron(II)-Loaded and to Zinc-Loaded Human Frataxin
Bernardo-Seisdedos, G;Schedlbauer, A;Pereira-Ortuzar, T;Mato, JM;Millet, O
LIFE-BASEL
2023-01-01
An NMR-Based Model to Investigate the Metabolic Phenoreversion of COVID-19 Patients throughout a Longitudinal Study
Gil-Redondo, R;Conde, R;Bizkarguenaga, M;Bruzzone, C;Lain, A;Gonzalez-Valle, B;Iriberri, M;Ramos-Acosta, C;Anguita, E;Lariz, JIA;Yandiola, PPE;Moran, MA;Jimenez-Mercado, ME;Egia-Mendikute, L;Seco, ...
METABOLITES
2022-12-01
A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants
Egia-Mendikute, L;Bosch, A;Prieto-Fernandez, E;Vila-Vecilla, L;Zanetti, SR;Lee, SY;Jimenez-Lasheras, B;del Rio, AG;Antonana-Vildosola, A;de Blas, A;Velasco-Beltran, P;Serrano-Macia, M;Iruzubieta, ...
FRONTIERS IN IMMUNOLOGY
2022-11-24
The use of pharmacological chaperones in rare diseases caused by reduced protein stability
Gil-Martinez, J;Bernardo-Seisdedos, G;Mato, JM;Millet, O
PROTEOMICS
2022-10-19
ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of ?-Aminolevulinate in Acute Porphyrias br
San Juan, I;Pereira-Ortuzar, T;Cendoya, X;Lain, A;To-Figueras, J;Mateos, B;Planes, FJ;Bernardo-Seisdedos, G;Mato, JM;Millet, O
BIOCHEMISTRY
2022-10-14
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis
Fondevila, MF;Fernandez, U;Heras, V;Parracho, T;Gonzalez-Rellan, MJ;Novoa, E;Porteiro, B;Alonso, C;Mayo, R;Lima, ND;Iglesias, C;Filliol, AA;Senra, A;Delgado, TC;Woodhoo, A;Herrero, L;Serra, ...
JOURNAL OF HEPATOLOGY
2022-07-01
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Martinez-Arranz, I;Bruzzone, C;Noureddin, M;Gil-Redondo, R;Minchole, I;Bizkarguenaga, M;Arretxe, E;Iruarrizaga-Lejarreta, M;Fernandez-Ramos, D;Lopitz-Otsoa, F;Mayo, R;Embade, N;Newberry, E;Mittendorf, ...
HEPATOLOGY
2022-03-17
Exploration of Human Serum Lipoprotein Supramolecular Phospholipids Using Statistical Heterospectroscopy in n-Dimensions (SHY-n): Identification of Potential Cardiovascular Risk Biomarkers Related to SARS-CoV-2 Infection
Masuda, R;Lodge, S;Whiley, L;Gray, N;Lawler, N;Nitschke, P;Bong, SH;Kimhofer, T;Loo, RL;Boughton, B;Zeng, AX;Hall, D;Schaefer, H;Spraul, M;Dwivedi, G;Yeap, BB;Diercks, T;Bernardo-Seisdedos, ...
ANALYTICAL CHEMISTRY
2022-03-15